Persistence of Inflammatory Phenotype in Residual Psoriatic Plaques in Patients on Effective Biologic Therapy
Authors:
- Shunya MashikoSMShunya Mashiko
- Rebecca M. EdelmayerRERebecca M. Edelmayer
- Yingtao BiYBYingtao Bi
- Lauren M. OlsonLOLauren M. Olson
- Joseph B. WetterJWJoseph B. Wetter
- Jing WangJWJing Wang
- Catherine MaariCMCatherine Maari
- Etienne Saint-Cyr ProulxEPEtienne Saint-Cyr Proulx
- Vivek KaimalVKVivek Kaimal
- Xuan LiXLXuan Li
- Katherine SalteKSKatherine Salte
- Sandra GarcetSGSandra Garcet
- 1 May 2020
- journal article
- research article
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 140 (5) , 1015-1025.e4
Abstract
No abstract availableKeywords
Funding Information
- AbbVie
This publication has 42 references indexed in Scilit:
- Combined Use of Laser Capture Microdissection and cDNA Microarray Analysis Identifies Locally Expressed Disease-Related Genes in Focal Regions of Psoriasis Vulgaris Skin LesionsJournal of Investigative Dermatology, 2012
- Heterogeneity of Inflammatory and Cytokine Networks in Chronic Plaque PsoriasisPLOS ONE, 2012
- Keratinocyte Apoptosis in Epidermal Remodeling and Clearance of Psoriasis Induced by UV RadiationJournal of Investigative Dermatology, 2011
- Mast Cells and Neutrophils Release IL-17 through Extracellular Trap Formation in PsoriasisThe Journal of Immunology, 2011
- Resolved Psoriasis Lesions Retain Expression of a Subset of Disease-Related GenesJournal of Investigative Dermatology, 2011
- Overrepresentation of IL-17A and IL-22 Producing CD8 T Cells in Lesional Skin Suggests Their Involvement in the Pathogenesis of PsoriasisPLOS ONE, 2010
- Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genesJournal of Allergy and Clinical Immunology, 2009
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)The Lancet, 2008
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)The Lancet, 2008
- Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trialJournal of the American Academy of Dermatology, 2008